The other trials were the origin from human primary NK cells, including ROBO1 for targeting solid tumor (NCT03940820), Mesothelin for targeting epithelial ovarian cancer (NCT03692637), PSMA for targeting prostate cancer (NCT03692663), CD22 for targeting refractory B cell lymphoma (NCT03692767), CD19 for targeting refractory B cell lymphoma (NCT03690310), CD19/CD22 for targeting metastatic solid tumors (NCT03824964), NKG2D for targeting relapsed and refractory B cell lymphoma (NCT03415100), and CD19/iCasp9/IL15 for targeting B cell non-Hodgkin lymphoma (NHL) (NCT03579927). Here, CD22 is linked to prostate carcinoma.